irinotecan hcl seacross 20 mgml
a.l. medi-market ltd. - irinotecan hydrochloride trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 20 mg / 1 ml - irinotecan - irinotecan hcl seacross is indicated for the treatment of patients with metastatic colorectal cancer: in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. for the treatment of patients with small cell lung cancer. for the treatment of patients with gastric cancer. irinotecan in combination with leucovorin, oxaliplatin and 5-fluorouracil for the first-line treatment of patients with metastatic pancreatic adenocarcinoma
burinex 1mg tablet blister pack
aft pharmaceuticals pty ltd - bumetanide, quantity: 1 mg - tablet, uncoated - excipient ingredients: agar; lactose monohydrate; maize starch; colloidal anhydrous silica; povidone; polysorbate 80; magnesium stearate; purified talc - burinex is indicated for the treatment of oedema, particularly that associated with congestive heart failure, hepatic and renal diseases including the nephrotic syndrome and acute pulmonary oedema.
pyridostigmine 30
rafa laboratories ltd - pyridostigmine bromide - tablets - pyridostigmine bromide 30 mg - pyridostigmine - pyridostigmine - pyridostigmine belongs to the cholinesterase inhibitor group and is indicated for the treatment of myasthenia gravis.
pyridostigmine 60
rafa laboratories ltd - pyridostigmine bromide - tablets - pyridostigmine bromide 60 mg - pyridostigmine - pyridostigmine - pyridostigmine belons to the cholinesterase inhibitor group and is indicated for the treatment of myasthenia gravis.
sterocort 4 mg
taro pharmaceutical industries ltd - triamcinolone - tablets - triamcinolone 4 mg - triamcinolone - triamcinolone - rheumatology: - active phases of systemic vasculitis: panarteritis nodosa (in patients with concomitant positive hepatitis b serology, the duration of treatment should be restricted to two weeks), polymyalgia rheumatica (pmr), pmr with giant cell arteritis, arteritis temporalis with acute visual loss;- active phases of systemic rheumatic disease: systemic lupus erythematosus, mixed connective tissue disease;- severe progressive forms of active rheumatoid arthritis, e.g. rapidly destructive forms and/or with extra-articular manifestations;- other forms of inflammatory rheumatic arthritis, provided that the severity of symptoms requires it and non-steroidal anti-inflammatory drugs (nsaids) cannot be used:spondylarthritis (ankylosing spondylitis with involvement of peripheral joints, psoriatic arthritis, enteropathic arthropathy with high inflammatory activity);- reactive forms of arthritis;- arthritis in sarcoidosis;- severe systemic form of juvenile idiopathic arthritis (still’s disease) or with iridocyclitis refractory to topical treatment.pulmonary and respiratory tract disorders: - bronchial asthma:for the long-term treatment of severe chronic asthma (category 4) and for treatment of exacerbations in adults and children.- chronic obstructive pulmonary disease (copd):for short-term treatment (max. 14 days) of exacerbations;- upper respiratory tract disorders:for short-term treatment of severe forms of allergic rhinitis in adults after failure of all other treatment alternatives, including topical glucocorticoids.dermatology: - oral initial treatment of extensive, severe, acute skin conditions responsive to glucocorticoids, such as: allergic skin disease (e.g. acute urticaria, contact dermatitis, drug eruption), atopic eczema (acute exacerbations or extensive weeping eczema), pemphigus vulgaris.nephrology: - minimal change glomerulonephritis;- extracapillary proliferative glomerulonephritis (rapidly progressive glomerulonephritis), generally in combination with cytostatics, tapering and ending treatment in goodpasture’s syndrome; for all other forms, long-term continuation of treatment;- idiopathic retroperitoneal fibrosis.
mannitolvioser solution for infusion 20 %
eldan electronic instruments co ltd, israel - mannitol - solution for infusion - mannitol 200 mg/ml - mannitol - mannitol 20%, solution for infusion is indicated for: - the promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established; - the reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass; - the reduction of elevated intraocular pressure when the pressure cannot be lowered by other means, and promoting the urinary excretion of toxic substances
isotroy liquid for inhalation
troikaa pharmaceuticals ltd - isoflurane - liquid for inhalation - 100%
suxamethonium accord suxamethonium chloride dihydrate 100 mg/2 ml solution for injection pre-filled syringe
accord healthcare pty ltd - suxamethonium chloride dihydrate, quantity: 100 mg - injection, solution - excipient ingredients: water for injections - for the production of skeletal muscle relaxation in anaesthesia. suited for procedures requiring only brief relaxation such as endotracheal intubation, endoscopic examinations, orthopaedic manipulations, short surgical procedures and electro-convulsive therapy.
ionsys
janssen-cilag international nv - fentanyl hydrochloride - pain, postoperative - analgesics - management of acute moderate to severe post-operative pain for use in a hospital setting only
rapaid itch relief cream
mundipharma pty ltd - melaleuca oil -